María Reig - Concepedia

Author

María Reig

Also Known As

Alba Diaz, Guha, Chandan, Jordi Bruix, M Reig, M. Reig, M., Reig, M.E. Reig, M.E. Reig Monzon, Marco Maggioni, Maria E. Reig

356

Publications

25.8K

Citations

H-Index

Concepts

All Affiliations

Universitat de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic de Barcelona Clinica Universidad de Navarra

About

María Reig is an author at Universitat de Barcelona specializing in medicine, hepatology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	4.4K
2	Health Sciences	14	14	1.9K
3	Engineering	3	3	93
4	Public Health	1	1	73
5	Biochemistry	1	1	21

María Reig

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy María Reig, Zoe Mariñó, Christie Perelló, Journal of Hepatology HepatologyHepatitis CHcv-related HccViral HepatitisHigh Rate	2016	1K
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial Riccardo Lencioni, Josep M. Llovet, Guohong Han, Journal of Hepatology Doxorubicin-eluting BeadsIntermediate Stage HccPharmacologyClinical TrialsPharmacotherapy	2016	680
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design Marta Burrel, María Reig, Alejandro Forner, Journal of Hepatology HepatologyDrug Eluting BeadsMedicineTrial DesignSurgery	2012	471
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma Alejandro Forner, Carmen Ayuso, Marı́a Varela, Cancer	2008	422
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic, The Lancet Oncology Second-line TreatmentHepatologyMedicinePharmacologyPharmacotherapy	2018	340
Intrahepatic Peripheral Cholangiocarcinoma in Cirrhosis Patients May Display A Vascular Pattern Similar to Hepatocellular Carcinoma on Contrast-Enhanced Ultrasound R. Vilana, Alejandro Forner, Luís Bianchi, Hepatology	2010	313
Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma # † Jordi Rimola, Alejandro Forner, María Reig, Hepatology	2009	296
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma Domenico Alvaro, Gregory J. Gores, Joël Walicki, Journal of Hepatology Surgical OncologyHepatologyMedicineHepatobiliary TumorBiliary Cancer	2023	263
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study Jordi Bruix, Won Young Tak, Antonio Gasbarrini, European Journal of Cancer	2013	254
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254

Page 1